VYVANSE

takeda canada inc🇨🇦 Health Canada

Approval Id: baa09087fea9258f
Drug Approval Canada Name: VYVANSE
Product Name: VYVANSE
Status: Marketed
Status Date: 2021-12-15
Original Market Date: 2019-08-06
Din: 02490277
Drug Class: Human
Dosage Form: Tablet (Chewable)
Route Of Administration: Oral
Schedule: Schedule G (CDSA I)
Ahfs: 28:20.04
Atc Original: N06BA12 LISDEXAMFETAMINE
Atc Name: n 06 ba 12
Aig Number: 0152536005
Company Name: takeda canada inc
Company Address: 3800, 22 Adelaide Street West, Toronto, Ontario, Canada, M5H 4E3

LISDEXAMFETAMINE DIMESYLATE

60 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

baa09087fea9258f

Type

Standard